Parkinson’s disease (PD) is one of the most common neurological disorder diseases which takes place when brain cells gradually die. PD is considered a challengeable disease because of the similarities between PD and other brain disorders. For this reason, there are several ways to diagnose PD. Nuclear medicine can be a solution to distinguish the similarities between some brain disorders and PD. The aim of this review is to understand the differences between three radiopharmaceuticals used to diagnose PD and to list the advantages and disadvantages of using each radiopharmaceutical. This review includes studies from 2014 to 2019. Every study published before 2014 was excluded. The database used for this search was found in PubMed. English filters and best matches were used to minimize the outcomes. The comparison between PD nuclear medicine agents was established according to three main points: availability and the length of the scan, sensitivity and specificity, and visual evolution. It would appear that using TRODAT 99mTc can be helpful for some departments that other agents cannot offer, especially 123I. However, using MIBG as a biomarker increases the specificity in some studies. MIBG 123I can be used with TRODAT 99mTc as a biomarker. Moreover, applying PET/CT agents can be studied and researched along with nuclear medicine agents. More research studies are needed to understand the relation between cardiac uptake and PD.
| Published in | Clinical Medicine Research (Volume 11, Issue 1) |
| DOI | 10.11648/j.cmr.20221101.12 |
| Page(s) | 6-12 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2024. Published by Science Publishing Group |
SPECT, Parkinson’s Disease, TRODAT, DaTscan
| [1] | Liu Z-Y, Liu F-T, Zuo C-T, Koprich JB, Wang J. Update on Molecular Imaging in Parkinson’s Disease. Neuroscience Bulletin. 2017; 34 (2): 330-340. doi: 10.1007/s12264-017-0202-6. |
| [2] | NIH Fact Sheets. National Institutes of Health. https://report.nih.gov/. Accessed July 15, 2021. |
| [3] | Pagano G, Niccolini F, Politis M. Imaging in Parkinson’s disease. Clinical Medicine. 2016; 16 (4): 371-375. doi: 10.7861/clinmedicine.16-4-371. |
| [4] | Mettler F. Essentials of Nuclear Medicine Imaging. Elsevier; 2019. |
| [5] | Djang DSW, Janssen MJR, Bohnen N, et al. SNM Practice Guideline for Dopamine Transporter Imaging with 123I-Ioflupane SPECT 1.0. Journal of Nuclear Medicine. 2011; 53 (1): 154-163. doi: 10.2967/jnumed.111.100784. |
| [6] | Gallo EF. Disentangling the diverse roles of dopamine D2 receptors in striatal function and behavior. Neurochemistry International. 2019; 125: 35 46. doi: 10.1016/j.neuint.2019.01.022. |
| [7] | ASAHI T, KASHIWAZAKI D, YONEYAMA T, NOGUCHI K, KURODA S. Importance of 123Iioflupane SPECT and Myocardial MIBG Scintigraphy to Determine the Candidate of Deep Brain Stimulation for Parkinson’s Disease. Neurologia medico-chirurgica. 2016; 56 (3): 125-131. doi: 10.2176/nmc.oa.2015-0234. |
| [8] | Booth TC, Nathan M, Waldman AD, Quigley A-M, Schapira AH, Buscombe J. The Role of Functional Dopamine-Transporter SPECT Imaging in Parkinsonian Syndromes, Part 1. American Journal of Neuroradiology. 2014; 36 (2): 229-235. doi: 10.3174/ajnr.a3970. |
| [9] | Tzen K-Y, Lu C-S, Yen T-C, Wey S-P, Ting G. Differential Diagnosis of Parkinson's Disease and Vascular Parkinsonism by 99mTc-TRODAT-1. Journal of Nuclear Medicine.https://jnm.snmjournals.org/content/42/3/408/tab-article-info. Published March 1, 2001. Accessed July 15, 2021. |
| [10] | Mozley PD, Schneider JS, Acton PD, et al. Binding of [99mTc]TRODAT-1 to Dopamine Transporters in Patients with Parkinson's Disease and in Healthy Volunteers. Journal of Nuclear Medicine. https://jnm.snmjournals.org/content/41/4/584.long. Published April 1, 2000. Accessed July 15, 2021. |
| [11] | Uyama N, Otsuka H, Shinya T, et al. The utility of the combination of a SPECT study with [123I]-FPCIT of dopamine transporters and [123I]-MIBG myocardial scintigraphy in differentiating Parkinson disease from other degenerative parkinsonian syndromes. Nuclear Medicine Communications. 2017; 38 (6): 487-492. doi: 10.1097/mnm.0000000000000674. |
| [12] | Yoshii F, Ryo M, Baba Y, Koide T, Hashimoto J. Combined use of dopamine transporter imaging (DAT-SPECT) and 123 I-metaiodobenzylguanidine (MIBG) myocardial scintigraphy for diagnosing Parkinson's disease. Journal of the Neurological Sciences. 2017; 375: 80-85. doi: 10.1016/j.jns.2017.01.042. |
| [13] | Ferraz HB. Dopamine Transporter Imaging Using 99mTc-TRODAT-1 SPECT in Parkinson’s Disease. Medical Science Monitor. 2014; 20: 1413-1418. doi: 10.12659/msm.890522. |
| [14] | Mittal BR, Sood A, Shukla J, et al. 99mTc-TRODAT-1 SPECT/CT imaging as a complementary biomarker in the diagnosis of parkinsonian syndromes. Nuclear Medicine Communications. 2018; 39 (4): 312-318. doi: 10.1097/mnm.0000000000000802. |
| [15] | Sasannezhad P, Juibary AG, Sadri K, et al. 99mTc-TRODAT-1 SPECT Imaging in Early and Late Onset Parkinson's Disease. Asia Oceania journal of nuclear medicine & biology. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482916/. Published 2017. Accessed July 15, 2021. |
| [16] | Kim DH, Wit H, Thurston M. Artificial intelligence in the diagnosis of Parkinson’s disease from ioflupane-123 single-photon emission computed tomography dopamine transporter scans using transfer learning. Nuclear Medicine Communications. 2018; 39 (10): 887-893. doi: 10.1097/mnm.0000000000000890. |
| [17] | Boschi A, Martini P, Pasquali M, Uccelli L. Recent achievements in Tc-99m radiopharmaceutical direct production by medical cyclotrons. Drug Development and Industrial Pharmacy. 2017; 43 (9): 1402-1412. doi: 10.1080/03639045.2017.1323911. |
| [18] | Choi SR, Kung M-P, Plössl K, Meegalla S, Kung HF. An improved kit formulation of a dopamine transporter imaging agent: [Tc-99m]TRODAT-1. Nuclear Medicine and Biology. 1999; 26 (4): 461-466. doi: 10.1016/s0969-8051 (99)00010-4. |
| [19] | Fallahi B, Esmaeili A, Beiki D, et al. Evaluation of 99mTc-TRODAT-1 SPECT in the diagnosis of Parkinson’s disease versus other progressive movement disorders. Annals of Nuclear Medicine. 2015; 30 (2): 153-162. doi: 10.1007/s12149-015-1042-y. |
| [20] | Kowalsky RJ, Perry JR. Radiopharmaceuticals in Nuclear Medicine Practice. Norwalk, CT: Appleton & Lange; 1987. |
| [21] | Palumbo B, Fravolini ML, Buresta T, et al. Diagnostic Accuracy of Parkinson Disease by Support Vector Machine (SVM) Analysis of 123I-FP-CIT Brain SPECT Data. Medicine. 2014; 93 (27). doi: 10.1097/md.0000000000000228. |
| [22] | Yamashina S, Yamazaki J-ichi. Neuronal imaging using SPECT. European Journal of Nuclear Medicine and Molecular Imaging. 2007; 34 (6): 939-950. doi: 10.1007/s00259-006-0359-0 |
| [23] | Prashanth R, Dutta Roy S, Mandal PK, Ghosh S. High-Accuracy Classification of Parkinson's Disease Through Shape Analysis and Surface Fitting in 123I-Ioflupane SPECT Imaging. IEEE Journal of Biomedical and Health Informatics. 2017; 21 (3): 794-802. doi: 10.1109/jbhi.2016.2547901. |
| [24] | Nuvoli S, Spanu A, Piras MR, et al. 123I-ioflupane brain SPECT and 123I-MIBG cardiac planar scintigraphy combined use in uncertain parkinsonian. |
APA Style
Jaber Abdulwahab Asiri, Sami Ahmed Kulaybi, Fatimah Ahmed Daghas, Ali Ibrahim Aamry. (2022). SPECT Ioflupane123I (DaTscan), 99mTc (TRODAT) and Ioflupane with Myocardial Scintigraphy 123I (MIBG) for Diagnosis of Parkinson’s Disease. Clinical Medicine Research, 11(1), 6-12. https://doi.org/10.11648/j.cmr.20221101.12
ACS Style
Jaber Abdulwahab Asiri; Sami Ahmed Kulaybi; Fatimah Ahmed Daghas; Ali Ibrahim Aamry. SPECT Ioflupane123I (DaTscan), 99mTc (TRODAT) and Ioflupane with Myocardial Scintigraphy 123I (MIBG) for Diagnosis of Parkinson’s Disease. Clin. Med. Res. 2022, 11(1), 6-12. doi: 10.11648/j.cmr.20221101.12
AMA Style
Jaber Abdulwahab Asiri, Sami Ahmed Kulaybi, Fatimah Ahmed Daghas, Ali Ibrahim Aamry. SPECT Ioflupane123I (DaTscan), 99mTc (TRODAT) and Ioflupane with Myocardial Scintigraphy 123I (MIBG) for Diagnosis of Parkinson’s Disease. Clin Med Res. 2022;11(1):6-12. doi: 10.11648/j.cmr.20221101.12
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.cmr.20221101.12,
author = {Jaber Abdulwahab Asiri and Sami Ahmed Kulaybi and Fatimah Ahmed Daghas and Ali Ibrahim Aamry},
title = {SPECT Ioflupane123I (DaTscan), 99mTc (TRODAT) and Ioflupane with Myocardial Scintigraphy 123I (MIBG) for Diagnosis of Parkinson’s Disease},
journal = {Clinical Medicine Research},
volume = {11},
number = {1},
pages = {6-12},
doi = {10.11648/j.cmr.20221101.12},
url = {https://doi.org/10.11648/j.cmr.20221101.12},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.cmr.20221101.12},
abstract = {Parkinson’s disease (PD) is one of the most common neurological disorder diseases which takes place when brain cells gradually die. PD is considered a challengeable disease because of the similarities between PD and other brain disorders. For this reason, there are several ways to diagnose PD. Nuclear medicine can be a solution to distinguish the similarities between some brain disorders and PD. The aim of this review is to understand the differences between three radiopharmaceuticals used to diagnose PD and to list the advantages and disadvantages of using each radiopharmaceutical. This review includes studies from 2014 to 2019. Every study published before 2014 was excluded. The database used for this search was found in PubMed. English filters and best matches were used to minimize the outcomes. The comparison between PD nuclear medicine agents was established according to three main points: availability and the length of the scan, sensitivity and specificity, and visual evolution. It would appear that using TRODAT 99mTc can be helpful for some departments that other agents cannot offer, especially 123I. However, using MIBG as a biomarker increases the specificity in some studies. MIBG 123I can be used with TRODAT 99mTc as a biomarker. Moreover, applying PET/CT agents can be studied and researched along with nuclear medicine agents. More research studies are needed to understand the relation between cardiac uptake and PD.},
year = {2022}
}
TY - JOUR T1 - SPECT Ioflupane123I (DaTscan), 99mTc (TRODAT) and Ioflupane with Myocardial Scintigraphy 123I (MIBG) for Diagnosis of Parkinson’s Disease AU - Jaber Abdulwahab Asiri AU - Sami Ahmed Kulaybi AU - Fatimah Ahmed Daghas AU - Ali Ibrahim Aamry Y1 - 2022/03/09 PY - 2022 N1 - https://doi.org/10.11648/j.cmr.20221101.12 DO - 10.11648/j.cmr.20221101.12 T2 - Clinical Medicine Research JF - Clinical Medicine Research JO - Clinical Medicine Research SP - 6 EP - 12 PB - Science Publishing Group SN - 2326-9057 UR - https://doi.org/10.11648/j.cmr.20221101.12 AB - Parkinson’s disease (PD) is one of the most common neurological disorder diseases which takes place when brain cells gradually die. PD is considered a challengeable disease because of the similarities between PD and other brain disorders. For this reason, there are several ways to diagnose PD. Nuclear medicine can be a solution to distinguish the similarities between some brain disorders and PD. The aim of this review is to understand the differences between three radiopharmaceuticals used to diagnose PD and to list the advantages and disadvantages of using each radiopharmaceutical. This review includes studies from 2014 to 2019. Every study published before 2014 was excluded. The database used for this search was found in PubMed. English filters and best matches were used to minimize the outcomes. The comparison between PD nuclear medicine agents was established according to three main points: availability and the length of the scan, sensitivity and specificity, and visual evolution. It would appear that using TRODAT 99mTc can be helpful for some departments that other agents cannot offer, especially 123I. However, using MIBG as a biomarker increases the specificity in some studies. MIBG 123I can be used with TRODAT 99mTc as a biomarker. Moreover, applying PET/CT agents can be studied and researched along with nuclear medicine agents. More research studies are needed to understand the relation between cardiac uptake and PD. VL - 11 IS - 1 ER -
Email: